唐氏综合征患者对生长激素的生长及生长调节素反应
Growth and somatomedin responses to growth hormone in Down's syndrome.
作者信息
Annerén G, Sara V R, Hall K, Tuvemo T
出版信息
Arch Dis Child. 1986 Jan;61(1):48-52. doi: 10.1136/adc.61.1.48.
Five growth retarded children with Down's syndrome, three girls and two boys aged between 3 1/2 and 6 1/2 years with trisomy 21, were treated with human growth hormone for six months. Before treatment the growth hormone response to sleep and insulin-arginine load, as well as serum concentrations of insulin, thyroid hormones, and cortisol was found to be in the normal range. During the treatment with human growth hormone the growth velocity increased in all the children with Down's syndrome from 2.3-2.8 cm to 3.3-5.8 cm per six months. The serum concentrations of immunoreactive insulin like growth factor 1 (IGF-1) were low before treatment and increased during the treatment with human growth hormone. The serum concentrations of immunoreactive insulin like growth factor 2 (IGF-2), which were within the normal range, however, increased during treatment with human growth hormone. Children with Down's syndrome respond to treatment with human growth hormone, with an increase in both growth velocity and serum somatomedin concentrations.
五名患有唐氏综合征的生长发育迟缓儿童，年龄在3岁半至6岁半之间，均为21三体综合征，其中三名女孩，两名男孩，接受了六个月的人生长激素治疗。治疗前，发现其对睡眠和胰岛素-精氨酸负荷的生长激素反应以及胰岛素、甲状腺激素和皮质醇的血清浓度均在正常范围内。在接受人生长激素治疗期间，所有唐氏综合征儿童的生长速度从每六个月2.3 - 2.8厘米增加到3.3 - 5.8厘米。治疗前免疫反应性胰岛素样生长因子1（IGF-1）的血清浓度较低，在人生长激素治疗期间升高。免疫反应性胰岛素样生长因子2（IGF-2）的血清浓度在正常范围内，但在人生长激素治疗期间也有所升高。唐氏综合征儿童对人生长激素治疗有反应，生长速度和血清生长调节素浓度均增加。
Zotero 插件